Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a new analysis of its Phase 3 SCORED clinical trial demonstrating the protective effects of sotagliflozin in patients with diabetic kidney ...
Socioeconomic factors such as education, occupation, and wealth influence the likelihood of developing cognitive impairment or dementia in later life and whether a person is likely to recover ...